clinical trial · NCT04321070
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries, Inc.·phase1·completed·n = 550
Acne VulgarisClindamycin PhosphateClindamycin Phosphate RLDPlacebos
brief summary
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
started
Sep 9, 2019
primary completion
Dec 14, 2019
completion
Mar 6, 2020
last updated
Apr 10, 2025
detailed description
Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris
official title
A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol